

# GLOBAL VACCINE & IMMUNIZATION RESEARCH FORUM 2023

## Plenary Session 1:

From GVAP to IA2030: Roles of Vaccine R&D to Enable Success

# Overview of GVAP and IA2030

---

***B.F. “Lee” Hall, MD, PhD, FIDSA***  
***Parasitology & International Programs Branch***  
***Division of Microbiology & Infectious Diseases***  
***NIAID***  
***28 March 2023***



BILL & MELINDA  
GATES *foundation*



# GVIRF:

## Historical Origins & Perspective

---

- **World Economic Forum 2010, Davos:**

**Bill and Melinda Gates Pledge  
US\$ 10 Billion in Call for  
“Decade of Vaccines”**

Jan 29, 2010

“We must make this the decade of vaccines,” said Bill Gates, speaking at the World Economic Forum Annual Meeting in Davos.

“Vaccines already save and improve millions of lives in developing countries.”

# Why a “Decade of Vaccines”?

---

- **Significant impact of immunization in the past decades**
  - *Progress with disease elimination or eradication*
  - *Millions of deaths averted*
- **Ability to deliver immunization with high coverage**
  - *Already reaching >80% children globally*
  - *Higher than any other intervention across the continuum of care*
- **Increasing number of diseases now vaccine preventable**
  - *Robust vaccine pipeline*
  - *Progress with adding vaccines into national programs*
- **Despite many successes, opportunities to do much better**

# Mission of the Decade of Vaccines





**"ATTAINMENT OF A WORLD IN WHICH ALL PEOPLE AT RISK ARE PROTECTED AGAINST VACCINE-PREVENTABLE DISEASES"**




***In 2010 a Decade of Vaccines Collaboration (DoVC) was established to coordinate the development of a Global Vaccine Action Plan to provide a framework for accomplishing the mission.***

# Outputs of the Decade of Vaccines Collaboration



# The GVAP Differed Significantly from Prior Vaccine Initiatives

---



- **Explicitly included an R&D component**
  - *Basic & Translational*
  - *Implementation*
  - *Operational*
- **Explicitly included an M&E/ Accountability component and framework**
- **Endorsed by the World Health Assembly 2012/2013**

# R&D Reporting

---

- **Scheduled to take place every 2 years**
- **Global Vaccine & Immunization Research Forum**
  - *4 - 6 March 2014, Bethesda MD, USA*
  - *15-17 March 2016, Johannesburg, South Africa*
  - *20-22 March 2018, Bangkok, Thailand*
  - *2020 – cancelled due to COVID GPHE*
  - *2021 – held virtually*
  - *28-30 March 2023, Seoul, South Korea*

# Evolution of GVIRF Themes

---

■ ***Discovery***

■ ***Development***

■ ***Decision Making***



■ ***Delivery***

■ ***End-to-End  
Integration***

■ ***Equity***

# Envisioning Vaccines & Immunization

---



***“...a world in which all individuals and communities enjoy lives free from vaccine-preventable diseases.”***

***“ A world where everyone, everywhere, at every age, fully benefits from vaccines for good health and well-being.”***



# IA2030: Translating Vision into Impact

## Vision

## Impact Goals

*“ A world where everyone,  
everywhere, at every age,...*



*Reduce mortality and morbidity from  
vaccine-preventable diseases for everyone  
**throughout the life course.***

*...fully benefits from  
vaccines...*



***Leave no one behind**, by increasing  
**equitable access** and use of **new and  
existing vaccines.***

*...for good health and well-  
being.”*



*Ensure good health and well-being for  
everyone by **strengthening immunisation  
within primary health care** and  
**contributing to universal health coverage  
and sustainable development.***

# IA2030 Strategic Framework

7 strategic  
priorities

*informed by*

4 core  
principles

Vision: A world where everyone, everywhere, at every age, fully benefits from vaccines for good health and wellbeing



# **GVIRF 2023: Goals**

---

- **Track progress and challenges related to priority vaccine research and development (R&D), including progress in achieving IA2030 SP7 R&D strategic objectives and goals**
- **Identify gaps, opportunities, and actions for the R&D community in the areas of vaccines and immunization**
- **Create opportunities for networking and collaboration among the vaccine R&D and immunization communities**
- **Expand capabilities of engagement with end users**
- **Enable innovation and development of new vaccines**
- **Accelerate development, licensing, and update of vaccines**
- **Improve program efficiencies and increase vaccine coverage**



**Thank You!**

---